A post on conflicts of interest in academic research, personal interests of scientists and the motivation to build a private company.
The German Federal Institute for Drugs and Medical Devices (BfArM) approved our study on “Efficacy and Safety of Psilocybin in Treatment-Resistant Depression” (EPIsoDE).
Our study with psylocin in depression was recommended for funding from the German Federal Ministry of Education and Research.
A TV broadcast in the German WDR on the renaissance of psychedelics, especially on the use of LSD “microdosing”, but also on their therapeutical potential.
My lecture on “Hot Topic: Psychopharmaka”, held in Mainz on March 15th, 2019, as part of the teaching event “Psychiatrie Update 2019”, was videotaped.
A brief post on some interviews I gave recently on esketamine for treatment-resistant depression and depression in women who have problems getting pregnant.
The US FDA approved esketamine nasal spray on March 5th, 2019, while deaths from synthetic opioids and suicides hit a record high in 2017.
Janssen Pharmaceuticals announced that the company on September 4th, 2018, submitted a New Drug Application to the US FDA for esketamine nasal spray for treatment-resistant depression.
The problem of withdrawal syndromes and emotional blunting occurring with prolonged antidepressant treatment is constantly underestimated by clinicians.
An article on the front page of the New York Times on April 7, 2018, has fueled the debate over antidepressants again.